Erschienen in:
08.08.2022 | ASO Author Reflections
ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer
verfasst von:
Austin D. Williams, MD, MSEd, Andrea V. Barrio, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2022
Einloggen, um Zugang zu erhalten
Excerpt
The use of neoadjuvant chemotherapy (NAC) in patients with operable breast cancer has increased in the past decade, with the goal of preserving the breast and avoiding axillary lymph node dissection (ALND). Breast cancer incidence is higher in women over the age of 65 years;
1 however, older patients undergo NAC less frequently, owing to concerns about medical comorbidities, adverse events, and potentially lower response rates compared with younger women.
2 We sought to better understand the clinical benefit and tolerability of NAC among patients ≥ 70 years of age compared with younger women 50–69 years of age. …